U.S. Stock Market Midday Update

Azitra, down 11.26%, with increased trading volume and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Stocks with High Trading Volume in the Industry

Apogee Therapeutics up 0.22%. Based on recent key news:

1. On June 22, AbbVie announced the acquisition of Apogee Therapeutics for $135.11 per share in cash, totaling approximately $10.9 billion, a 49% premium over the closing price. This news drove Apogee's stock price up about 54% in pre-market trading. Source: Zhitong Finance

2. On June 23, Apogee Therapeutics' stock price hit a record high, rising nearly 47% in pre-market trading, as the market focused on its treatment pipeline progress. Source: Reuters

3. On June 23, RBC Capital raised its target price for Apogee Therapeutics from $97 to $135, reflecting the transaction value. Source: Barron's The biotech industry is experiencing frequent acquisition activities, with significant capital inflow.

AbbVie up 1.58%. Based on recent key news:

1. On June 22, AbbVie announced the acquisition of Apogee Therapeutics for approximately $10.9 billion, strengthening its immunology product line. This move pushed AbbVie's stock price up 1.58%. Source: Barron's

2. On June 23, Guojin Securities pointed out that AbbVie's acquisition of Apogee shows its strategic value expectations for long-acting AD assets, further validating the market potential of long-acting AD products. Source: Zhitong Finance

3. On June 22, JPMorgan analysts believe that AbbVie's acquisition of Apogee is highly compatible and will help expand the product pipeline in immunology and atopic dermatitis. Source: Investing.com The pharmaceutical industry continues to see a wave of mergers and acquisitions, with attention to risks.

Gilead Sciences up 0.74%. Based on recent news,

1. On June 23, Gilead Sciences submitted a supplemental application supporting Trodelvy for first-line treatment in adult patients with unresectable locally advanced or metastatic TNBC. This move could make Trodelvy a potential foundational treatment for 1L metastatic TNBC in Europe under PD-L1 status, driving the stock price up.

2. On June 23, the European Commission approved Gilead's Trodelvy as a first-line monotherapy for patients with metastatic TNBC. This decision is based on ASCENT-03 data, showing a 38% reduction in the risk of disease progression or death compared to standard chemotherapy, further boosting market confidence On June 23, the EMA is reviewing Gilead's application for the combined use of Keytruda with Trodelvy for PD-L1 positive metastatic TNBC patients. This news has increased market expectations for Gilead's future growth, driving up its stock price. The biopharmaceutical industry has performed strongly recently, with noticeable capital inflows.

Stocks ranked among the top in industry market capitalization

Amgen rose by 0.79%. Based on recent news,

1. On June 23, Amgen reported a 6% year-on-year increase in first-quarter revenue, reaching $8.6 billion. Despite losing patent protection for the bone health drug denosumab, other products such as Tezspire and Tepezza performed well, driving up the stock price.

2. On June 22, analysts maintained a hold rating on Amgen but believe that five other stocks offer better investment value. Analysts' cautious stance may exert some pressure on the stock price.

3. On June 22, Amgen released original content emphasizing its advantages in revenue growth and dividends, attracting the attention of long-term investors. The biopharmaceutical industry has performed strongly recently